Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
1989 1
1990 1
1991 1
1997 1
1998 3
1999 2
2004 2
2006 3
2012 3
2014 1
2017 4
2018 5
2019 1
2020 2
2021 6
2022 9
2023 6
2024 5
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

54 results

Results by year

Filters applied: . Clear all
Page 1
Molecular Aspects Concerning the Use of the SARS-CoV-2 Receptor Binding Domain as a Target for Preventive Vaccines.
Valdes-Balbin Y, Santana-Mederos D, Paquet F, Fernandez S, Climent Y, Chiodo F, Rodríguez L, Sanchez Ramirez B, Leon K, Hernandez T, Castellanos-Serra L, Garrido R, Chen GW, Garcia-Rivera D, Rivera DG, Verez-Bencomo V. Valdes-Balbin Y, et al. Among authors: verez bencomo v. ACS Cent Sci. 2021 May 26;7(5):757-767. doi: 10.1021/acscentsci.1c00216. Epub 2021 Apr 19. ACS Cent Sci. 2021. PMID: 34075345 Free PMC article. Review.
Efficacy and Safety of a Protein-Based SARS-CoV-2 Vaccine: A Randomized Clinical Trial.
Mostafavi E, Eybpoosh S, Karamouzian M, Khalili M, Haji-Maghsoudi S, Salehi-Vaziri M, Khamesipour A, Jalali T, Nakhaeizadeh M, Sharifi H, Mansoori Y, Keramat F, Ghodrati S, Javanian M, Doroud D, Omrani MD, Asadi H, Pouriayevali MH, Ghasemian R, Farshidi H, Pourahmad M, Ghasemzadeh I, Mounesan L, Darvishian M, Mirjalili MR, Toledo-Romani ME, Valenzuela-Silva C, Verez-Bencomo V, Gouya MM, Emadi-Koochak H, Haghdoost AA, Biglari A; Soberana Study Group. Mostafavi E, et al. Among authors: verez bencomo v. JAMA Netw Open. 2023 May 1;6(5):e2310302. doi: 10.1001/jamanetworkopen.2023.10302. JAMA Netw Open. 2023. PMID: 37133864 Free PMC article. Clinical Trial.
Repeat-dose and local tolerance toxicity of SARS-CoV-2 FINLAY-FR-02 vaccine candidate in Sprague Dawley rats.
Oliva-Hernández R, Fariñas-Medina M, Hernández-Salazar T, Oyarzabal-Vera A, Infante-Bourzac JF, Rodríguez-Salgueiro S, Rodríguez-Noda LM, Arranguren-Masorra Y, Climent-Ruíz Y, Fernández-Castillo S, G-Rivera D, Santana-Mederos D, Sánchez-Ramírez B, García-Rivera D, Valdés-Barbín Y, Vérez-Bencomo V. Oliva-Hernández R, et al. Among authors: verez bencomo v. Toxicology. 2022 Apr 15;471:153161. doi: 10.1016/j.tox.2022.153161. Epub 2022 Mar 29. Toxicology. 2022. PMID: 35364223 Free PMC article.
SARS-CoV-2 RBD-Tetanus Toxoid Conjugate Vaccine Induces a Strong Neutralizing Immunity in Preclinical Studies.
Valdes-Balbin Y, Santana-Mederos D, Quintero L, Fernández S, Rodriguez L, Sanchez Ramirez B, Perez-Nicado R, Acosta C, Méndez Y, Ricardo MG, Hernandez T, Bergado G, Pi F, Valdes A, Carmenate T, Ramirez U, Oliva R, Soubal JP, Garrido R, Cardoso F, Landys M, Gonzalez H, Farinas M, Enriquez J, Noa E, Suarez A, Fang C, Espinosa LA, Ramos Y, González LJ, Climent Y, Rojas G, Relova-Hernández E, Cabrera Infante Y, Losada SL, Boggiano T, Ojito E, León K, Chiodo F, Paquet F, Chen GW, Rivera DG, Garcia-Rivera D, Verez Bencomo V. Valdes-Balbin Y, et al. Among authors: verez bencomo v. ACS Chem Biol. 2021 Jul 16;16(7):1223-1233. doi: 10.1021/acschembio.1c00272. Epub 2021 Jul 4. ACS Chem Biol. 2021. PMID: 34219448 Free article.
Evaluation of PastoCovac plus vaccine as a booster dose on vaccinated individuals with inactivated COVID-19 vaccine.
Farahmand B, Sadat Larijani M, Fotouhi F, Biglari A, Sorouri R, Bagheri Amiri F, Eslamifar A, Jalali T, Salehi-Vaziri M, Banifazl M, Dahmardeh S, Eshratkhah Mohammadnejad A, Bavand A, Tavakoli M, Verez-Bencomo V, Mostafavi E, Noori Daloii H, Ashrafian F, Saberpour M, Ramezani A. Farahmand B, et al. Among authors: verez bencomo v. Heliyon. 2023 Sep 29;9(10):e20555. doi: 10.1016/j.heliyon.2023.e20555. eCollection 2023 Oct. Heliyon. 2023. PMID: 37810803 Free PMC article.
A COVID-19 vaccine candidate composed of the SARS-CoV-2 RBD dimer and Neisseria meningitidis outer membrane vesicles.
Santana-Mederos D, Perez-Nicado R, Climent Y, Rodriguez L, Ramirez BS, Perez-Rodriguez S, Rodriguez M, Labrada C, Hernandez T, Diaz M, Orosa I, Ramirez U, Oliva R, Garrido R, Cardoso F, Landys M, Martinez R, Gonzalez H, Hernandez T, Ochoa-Azze R, Perez JL, Enriquez J, Gonzalez N, Infante Y, Espinosa LA, Ramos Y, González LJ, Valenzuela C, Casadesus AV, Fernandez B, Rojas G, Pérez-Massón B, Tundidor Y, Bermudez E, Plasencia CA, Boggiano T, Ojito E, Chiodo F, Fernandez S, Paquet F, Fang C, Chen GW, Rivera DG, Valdes-Balbin Y, Garcia-Rivera D, Verez Bencomo V. Santana-Mederos D, et al. Among authors: verez bencomo v. RSC Chem Biol. 2021 Dec 8;3(2):242-249. doi: 10.1039/d1cb00200g. eCollection 2022 Feb 9. RSC Chem Biol. 2021. PMID: 35360883 Free PMC article.
A randomized, double-blind phase I clinical trial of two recombinant dimeric RBD COVID-19 vaccine candidates: Safety, reactogenicity and immunogenicity.
Pérez-Rodríguez S, de la Caridad Rodríguez-González M, Ochoa-Azze R, Climent-Ruiz Y, Alberto González-Delgado C, Paredes-Moreno B, Valenzuela-Silva C, Rodríguez-Noda L, Perez-Nicado R, González-Mugica R, Martínez-Pérez M, Sánchez-Ramírez B, Hernández-García T, Díaz-Machado A, Tamayo-Rodríguez M, Martín-Trujillo A, Rubino-Moreno J, Suárez-Batista A, Dubed-Echevarría M, Teresa Pérez-Guevara M, Amoroto-Roig M, Chappi-Estévez Y, Bergado-Báez G, Pi-Estopiñán F, Chen GW, Valdés-Balbín Y, García-Rivera D, Verez-Bencomo V. Pérez-Rodríguez S, et al. Among authors: verez bencomo v. Vaccine. 2022 Mar 18;40(13):2068-2075. doi: 10.1016/j.vaccine.2022.02.029. Epub 2022 Feb 8. Vaccine. 2022. PMID: 35164986 Free PMC article. Clinical Trial.
Expanding the Scope of Ugi Multicomponent Bioconjugation to Produce Pneumococcal Multivalent Glycoconjugates as Vaccine Candidates.
Humpierre AR, Zanuy A, Saenz M, Garrido R, Vasco AV, Pérez-Nicado R, Soroa-Milán Y, Santana-Mederos D, Westermann B, Vérez-Bencomo V, Méndez Y, García-Rivera D, Rivera DG. Humpierre AR, et al. Among authors: verez bencomo v. Bioconjug Chem. 2020 Sep 16;31(9):2231-2240. doi: 10.1021/acs.bioconjchem.0c00423. Epub 2020 Sep 2. Bioconjug Chem. 2020. PMID: 32809806
54 results